|
1. Bernhard H Heidemann and John H McClure, Changes in maternal physiology during pregnancy CEACCP, Jun 2003; 3: 65 - 68. 2.W.A.H.J.Van Stiphout,A.Hofman , Bruijnserum,Lipids in young women before during and after pregnancy. Am.J.Epidemiol.. 1987; 126: 922-92 3.RossR.The pathogenesis of atherosclerosis:a perspective for the 1990s.Nature.362(6423):801-9.Review(1993) 4.LibbyP.Current concepts of the pathogenesis of the acute coronary syndrome.Circulation.104:365-372(2001) 5.Paul H. Black*, Lisa D. Garbutt(2002) ,Stress inflammation and cardiovascular disease Journal of Psychosomatic; Research 52,1–23 6.Davies, M.J., Richardson, P.D., and Woolf, N. (1993). Risk of thrombosis in human atherosclerotic plaques: role of extracellular ipid, macrophage, and smooth muscle cell content. Br. Heart J. 69,377–381. 7.Cuchel M, Rader DJ.(2002)The role of high density lipoproteins in thrombosis. ScientificWorldJournal. Jan 12;2(1):89-95. 8.Diaz MN, Frei B and Vita JA (1997) Antioxidants and atherosclerotic heart disease. N Engl J Med 337:408-416. 9.Galis, Z.S., Sukhova, G.K., Lark, M.W., and Libby, P. (1994).Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503. 10.Carmeliet, P. (2000). Proteins in cardiovascular aneurysms and rupture:targets for therapy? J. Clin. Invest. 105, 1519–1520. 11.M ason D P , K enagy R D , H asenstab D , et al. Matrix metalloproteinase-9 over expression enhances vascular smooth muscle cell migration and altersrem odeling in the injured rat carotid artery [J]. C irc R es, 1999, 85(12):1179-1185. 12.Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335–40. 13.Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., et al. (1997).Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellularcarcinoma in children. The New England Journal of Medicine, 336(26), 1855-1859. 14.Friedman SL. Cytokines and fibrogenesis. Semin. Liver Dis. 1999; 19: 129–40. 15.Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J. Hepatol. 1999; 30: 1090–8. 16.Takahara T, Furui K, Yata Y et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997; 26: 1521–9. 17.Arii S, Mise M, Harada T et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996; 24: 316–22. 18.Hayasaka A, Suzuki N, Fujimoto N et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996; 24: 1058–62. 19.Xu, G.F., et al., Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats. World J Gastroenterol, 2004. 10(24): p. 3621-7. 20.Benyon, R.C. and M.J. Arthur, Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis, 2001. 21(3): p. 373-84. 21.Pijuan Domenech A, Gatzoulis MA. Pregnancy and heart disease Rev Esp Cardiol. 2006 Sep;59(9):971-84. Review. Spanish 22.Yamada, Y., Doi, T., Hamakubo, T., and Kodama, T. (1998). Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell. Mol. Life .54,628–640. 23.Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG(2003)Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation ;107:1750-1756. 24.Tambunting, F., et al., Increased lung matrix metalloproteinase-9 levels in extremely premature baboons with bronchopulmonary dysplasia. Pediatr Pulmonol, 2005. 39(1): p. 5-14. 25.Iglesias, D., et al., Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J, 2005. 25(1): p. 104-9. 26.May, A.E., et al., Plasminogen and matrix metalloproteinase activation by enzymatically modified low density lipoproteins in monocytes and smooth muscle cells. Thromb Haemost, 2005. 93(4): p. 710-5. 27.Haruta I, Tokushige K, Komatsu T, Ikeda I, Yamauchi K, Hayashi N. Clinical implication of vascular cell adhesion molecule-1 and very late activation antigen−4 interaction, and matrix metalloproteinase-2 production in patients with liver disease. Can. J. Gastroenterol. 1999; 13: 721–7. 28.Chung TW, Kim JR, Suh JI, Lee YC, Chang YC, Chung TH, Kim CH. Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus.J Gastroenterol Hepatol. 2004 May;19(5):565-71. 29.Jiang, Z.Q., et al., [Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix]. Ai Zheng, 2003. 22(2): p. 178-84. 30.Wang, L., et al., [Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis]. Zhonghua Yi Xue Za Zhi, 2003. 83(9): p. 782-6. 31.Zhang, S., et al., Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol, 2003. 9(5): p. 899-904. 32.Chen, J.J., et al., Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol, 2005. 23(5): p. 953-64. 33.Gu, Z.D., et al., Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol, 2005. 11(6): p. 871-4. 34.De Vicente, J.C., et al., Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol, 2005. 41(3): p. 283-93. 35.Yamada, Y., Doi, T., Hamakubo, T., and Kodama, T. (1998). Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell. Mol. Life .54,628–640. 36.Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG(2003)Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation ;107:1750-1756. 37.Nagase H, Woessner JF Jr. (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494. 38.Sternlicht MD, Werb Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516. 39.Dollery CM, McEwwan JR, Henney AM. (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868. 40.S. L. Parsons, S. A. Watson, P. D. Brown, H. M. Collins, and R. J. C. Steele:Matrix metalloproteinases. British ournal of Surgery, Vol. 84, 160–166, 1997 41.Jukka Westermarck and Veli–Matti Khri:Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., Vol. 13, 781–792, 1999 42.Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. (1996) Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271:10672-10680. 43.Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89:201–210. 44.Spinale FG. (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90:520–530. 45.Galis ZS, Khatri JJ. (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262. 46.Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063-3070. 47.Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JPM, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevent cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 10:1135–1142. 48.Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55-62. 49.Barker, L. F., & Murray, R. (1972). Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. American Journal of the Medical Sciences, 263(1), 27-33. 50.Dienstag, J. L., & Isselvacher, K. J. (1994). Harrison''s Principles of Internal Medicine (13 ed.). New York: McGRAW-Hill. 51.De Clercq, E. Perspectives for the treatment of hepatitis B virus infections. J. Antimicrob. Agents 12: 81-95, 1999 52.Ganem, D., and Varmus, H. E. The molecular biology of the hepatitis Bviruses. Ann. Rev. Biochem. 56: 651-93, 1987. 53.Monjardino, J., 1998. Molecular biology of human hepatitis viruses.Imperial College Press pp21-61. 54.Murphy, F., et al., N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. Comp Hepatol, 2004. 3 Suppl 1: p. S8. 55.Gardi, C., et al., Effect of free iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol, 2002. 64(7): p. 1139-45. 56. Iredale, J.P., et al., Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 1998. 102(3): p. 538-49. 57.Arthur MJP. Degradation of matrix proteins in liver fibrosis. Pathol. Res. Pract. 1994; 190: 825–33. 58.Makkonen M, Puhakainen E, Hänninen O, Castrén O,Lactate dehydrogenase isoenzymes in human myometrium during pregnancy and labor. Acta Obstet Gynecol Scand. 1982;61(1):35-7. 59.R. Visse and H. Nagase, Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry, Circ Res 92 (2003), pp. 827–839. 60.M.P. Jacob, Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions, Biomed Pharmacother 57 (2003), pp. 195–202. 61.Brown, D. L., Hibbs, M. S., Kearney, M., Loushin, C. and Isner, J. M. (1995) Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91 , pp. 2125-2131. 62.Nagase H, Woessner Jr JF 1999 Matrix metalloproteinases. J Biol Chem 274:21491–21494 63.Woessner Jr JF, Nagase H 2000 Matrix metalloproteinases and TIMPs. New York: Oxford University Press 64.Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S 1994 Developmental regulation of 72 kD and 92 kD type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 171:832–838 65.Lippi G,Albiero A, et al., Lipid and lipoprotein profile in physiological pregnancy. Clin Lab. 2007;53(3-4):173-7. 66.Steinberg, D., and Witztum, J.L. (1999). Lipoproteins, Lipoprotein,Oxidation, and Atherogenesis, K.R. Chien, ed. (Philadelphia: W.B.Saunders Co.). 67.Navab, M., Berliner, J.A., Watson, A.D., Hama, S.Y., Territo, M.C.,Lusis, A.J., Shih, D.M., Van Lenten, B.J., Frank, J.S., Demer, L.L.,et al. (1996). The yin and yang of oxidation in the development ofthe fatty streak. Arterioscler. Thromb. Vasc. Biol. 16, 831–842. 68.Ross, R. (1999). Atherosclerosis— an inflammatory disease. N. Eng.J. Med 340, 115–126. 69.Montano, L., Miescher, G. C., Goodall, A. H., Wledimann, K. H., Janossy, G., & Thomas, H.C. (1982). Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology, 2(5), 557-561 70.Haruta I, Tokushige K, Komatsu T, Ikeda I, Yamauchi K, Hayashi N. Clinical implication of vascular cell adhesion molecule-1 and very late activation antigen−4 interaction, and matrix metalloproteinase-2 production in patients with liver disease. Can. J. Gastroenterol. 1999; 13: 721–7. 71.Chung TW, Kim JR, Suh JI, Lee YC, Chang YC, Chung TH, Kim CH. Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus. J Gastroenterol Hepatol. 2004 May;19(5):565-71. 72.Xu, L., et al., Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut, 2005. 54(1): p. 142-51. 73.Reif, S., et al., Matrix Metalloproteinases 2 and 9 Are Markers of Inflammation but Not of the Degree of Fibrosis in Chronic Hepatitis C. Digestion, 2005. 71(2): p. 124-130. 74.Jong GP, Ma T., et al., Serum MMP-9 activity as a diagnosing marker for the developing heart failure of post MI patients. Chin J Physiol. 2006 Apr 30;49(2):104-9 75.Ichiro Shimizu, Susumu Ito, Protection of estrogens against the progression of chronic liver disease. Hepatology Research Vol. 37 Issue 4 Page 239 April 2007
|